 By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Update on Phase 2b Trial of EB01 Edesa Biotech, Inc. NASDAQ:EDSA is currently conducting a Phase 2b clinical trial of EB01 2.0 cream in patients with ACD. The randomized, double blind, placebo controlled, sample size adaptive design trial is expected to enroll approximately 46 patients in Part A randomized 1:1 